% | $
Quotes you view appear here for quick access.

Merrimack Pharmaceuticals, Inc. Message Board

  • kennethmorris85 kennethmorris85 Oct 9, 2012 12:13 PM Flag


    Nothing is going to happen until next clinical trial results are out next year. Light trading is moving price down, but this is a $50 stock.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Mack has 8 novel compounds with 6 in the clinics all potential multi-billion dollar drugs in the area of greatest need---solid tumors. The company has excellent research capabilities and management that can take this company to be a leading biopharma. If ONE of the 8 compounds is approved this is a 10X and if more than one, then the skies the limit! I've owned this company for more than 8 years now (in a private placement that raised funds 8 times before coming to the public markets), when it's leading drug candidate was produced in goat's milk for autoimmune diseases. While they mishandled that potential drug, which should be on the market today for RA, and other autoimmune diseases, they have learned from their mistakes (phase 3 testing can not be taken for granted and to show efficacy, you really need to properly choose your patient population with great care) . The reward/risk ratio for this company is greater than any I've seen in my nearly 30 years of investing. Today's announcement, raising 200 MM in a shelf offering to help fund their myriad of trials is clearly a very positive sign, that the market, somewhat belatedly, took to heart! This company is not for the faint of heart. It is not a one or two year hold. But for the patient investor, this company truly has the potential to be a game (life) changer.



      • 2 Replies to alienfarm
      • Well, nice to hear from another long term holder. I've been in the stock for ten years now am more convinced than ever that my original gut level instincts were correct.

        Agree with all of your points and your point of view. I've been a biotech investor for a long time and think this is the best one I've ever seen as well. I'm particularly optimistic about 398 later this year and as well for the breast trial with 121. The pipeline is very deep, the science is solid, and management is first rate.

        I suspect the stock I bought in 2003 will end up in my kids portfolio when I'm no longer around. That's how 'long term' I am with Merrimack.

      • what shelf offering?

    • Mack is NOT a $50 stock. It's a $6.67/share stock.

6.20+0.05(+0.81%)Sep 28 4:00 PMEDT